All In MedTech

Device Trial Radar · NCT05411614

Hybrid Ablation of Atrial Fibrillation in Heart Failure

A Randomised Controlled Trial Comparing Convergent Hybrid Ablation to Catheter Ablation in Patients With Persistent Atrial Fibrillation and Heart Failure

Last checked: Nov 20, 2026Latest source record: Nov 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Jun 25, 2022

Primary completion

May 2026

Study completion Oct 2027

Sponsor

Lead sponsor
St. George's Hospital, LondonAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 9, 2022

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A randomised controlled trial to assess the efficacy of staged hybrid ablation when compared with standard catheter ablation in patients with non-paroxysmal atrial fibrillation (AF) and Heart Failure

Conditions

  • Persistent Atrial Fibrillation
  • Atrial Fibrillation, Persistent
  • Atrial Arrhythmia
  • Atrial Fibrillation
  • Heart Failure
  • Left Ventricular (LV) Systolic Dysfunction

Interventions

  • AtriCure EPi-Sense-AF Guided Coagulation System +/- AtriclipDevice

    Minimally-invasive epicardial ablation +/- left atrial appendage exclusion using an epicardial clip, combined with endocardial radiofrequency catheter ablation

  • Endocardial Catheter AblationDevice

    Standard percutaneous endocardial catheter ablation of atrial fibrillation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Freedom from persistent atrial arrhythmia after a single procedure (either the completed hybrid ablation or catheter ablation) off Class I or III medicationsTime frame: Measured from the end of a 3-month blanking period at 12 and 24 months

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Ashford & St Peters Hospital NHS Trust

    Chertsey, United Kingdom · Recruiting

  • Epsom General Hospital

    Epsom, United Kingdom · Recruiting

  • Cromwell Hospital

    London, United Kingdom · Active not recruiting

4 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.